Anticancer Therapies – Products

Terumo BCT and KBIOHealth have signed an MOU to develop workforce training for cell and gene therapy manufacturing in Korea. The program will focus on CAR-T and MSC therapy production using automated systems like Quantum Flex.

This content introduces the physiological and pathological importance of protein kinases, kinase inhibitors approved for clinical use, and next-generation kinase inhibitors.

Celonic Group, a “Pure Play” biologics contract development and manufacturing organization (CDMO), announced the signing of a multi-year commercial manufacturing agreement with LINDIS Biotech.

ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative anticancer virus platform, the SJ-600 series.

This application focus explores how high-plex spatial profiling can be applied to better understand the role of T cells in cancer immune surveillance and how cancers evade the immune system.

This whitepaper discusses the classification of bsAbs targeting immunomodulatory checkpoints and highlights their applications in cancer immunotherapy.

Transgene and ProBioGen, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line.

Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement.

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune diseases.

Nona Biosciences, announced that it has entered into a multi-target antibody discovery collaboration with Umoja Biopharma. This collaboration leverages Nona's proprietary fully human heavy chain only antibody (HCAb) technology.